Abstract
Background and aim COVID-19 disease raises many critical issues in dermatology and dermatological care. Addressing these issues is necessary, yet also challenging, because there are only a few direct data available. We attempted a study to provide a better understanding regarding the impact of COVID-19 pandemic on the course and management of chronic immune-mediated inflammatory skin disease during COVID-19 pandemic. Methods A Questionnaire based study was conducted on patients with chronic immune-mediated inflammatory skin diseases started on immunosuppressant therapy before COVID period and questioned regarding the treatment taken for skin disease, follow up, COVID-19 infection and vaccination status, flare up of skin disease, management of the disease flare up. The data collected are tabulated and analyzed in epi-info software/MS excel. Result Among 500 patients, 462 (92.4%) discontinued the treatment which was mainly due to their inability to reach the hospital (99.5%) and remaining 0.5% were afraid of taking immune suppressants during pandemic. 385 (83.3%) of 462 patients who discontinued the drug had disease flare up. 75 (15%) out of 500 patients turned COVID–19 positive. 50 (66.6%) out of 75 COVID-19 (+) patients developed disease flare up. 293 (58.6%) out of 500 patients were vaccinated, among which 12 patients (4%) had flare up. Conclusion COVID-19 infection as well as vaccination has both direct and indirect influence in disease progression/flare up of preexisting inflammatory dermatoses. Knowledge regarding the course and management of chronic inflammatory skin conditions during this pandemic helps in providing better quality of life.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call